CoChat

CRISPR /Cas‐mediated genome editing to treat EGFR ‐mutant lung cancer: a personalized molecular surgical therapy

Open access
Tang, Huibin, Shrager, Joseph B · 2016 · EMBO Molecular Medicine
Cited by 62

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

While substantial progress has been made in the treatment of lung cancer with the development of tyrosine kinase inhibitors ( TKI s) that target tumor‐driving mutations in the epidermal growth factor receptor ( EGFR ), nearly all patients treated with TKI s ultimately develop drug resistance due to resistance‐conferring genomic mutations. CRISPR /Cas9‐mediated genome editing is a powerful new technique that allows precise changes to be made to cells’ genomes. This technology is currently used widely in research laboratories, but it has yet to make an impact in the clinics. We suggest a potential exciting clinical application for this technical advance—allowing personalized, molecular surgery to correct or destroy the mutated EGFR . After detection of EGFR mutations in individual patients’ cancers from biopsy samples, the EGFR ‐mutant genes will be repaired or destroyed with virus‐delivered CRISPR /Cas system. We demonstrate the feasibility of such an approach with examples from the most common primary and secondary EGFR mutations that are encountered. These proposed “molecular surgeries” on genomic DNA directly target the cause of the disease in a personalized and possibly permanent manner. This approach could be combined with traditional surgery, radiation therapy, or chemo/targeted therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201506006

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 62

Metadata

Authors
Tang, H., & Shrager, J. B.
Venue
EMBO Molecular Medicine
Published
2016-01-08
Volume
8
Issue
2
Pages
83-85
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2223779374
Cited by
62
References
3
FWCI
3.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRISPR /Cas‐mediated genome editing to treat EGFR ‐mutant lung cancer: a personalized molecular surgical therapy. https://app.cochat.ai/papers/10.15252/emmm.201506006
The paper
Tang, H., & Shrager, J. B. (2016). CRISPR /Cas‐mediated genome editing to treat EGFR ‐mutant lung cancer: a personalized molecular surgical therapy. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201506006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.